• linkedin
  • Increase Font
  • Sharebar

    Fusion Bx-guided HIFU shows promise in localized PCa

    All patients completely continent at 6 months post treatment in Italian study

    Boston—Early follow-up of men with localized prostate cancer treated with novel technology that integrates fusion biopsy findings to guide high-intensity focused ultrasound (HIFU [Focal One]) shows the technique has promise for minimizing post-treatment morbidity while providing good cancer control, Italian researchers reported at the AUA annual meeting in Boston. 

    The device is approved for use in Europe and is currently under FDA review. The single-center study included 41 men with organ-confined prostate cancer and a Gleason score ≥3+3 who were followed prospectively for 6 months after treatment.

    Median preoperative PSA was 6.8 ng/mL. Twenty-nine men (70.8%) had low-risk disease, 10 men (24.4%) had intermediate-risk prostate cancer, and two men (5.8%) were in the high-risk category. Median pre-treatment prostate volume was 39.7 mL and median volume of tissue treated was 13.5 mL.

    Also see: Prostate MRI-Bx may ID partial gland ablation candidates

    At 6 months post treatment, median PSA was 2.4 ng/mL (range, 0.2 to 9.0 ng/mL), all patients were completely continent, and 30 of 31 men (96%) who were potent preoperatively maintained potency.

    Follow-up with multiparametric magnetic resonance imaging (mpMRI) at 6 months identified a focal abnormal signal around the treated area in a single patient. The latter individual underwent fusion biopsy that identified persistence of Gleason 3+3 microfocal cancer and was retreated with the HIFU focal therapy.

    “We believe this integrated path for focal fusion treatment that is performed using the latest generation technology for diagnostic imaging and HIFU is allowing the most accurate detection and precise treatment of index foci of prostate cancer,” said Giulio Milanese, MD, a urologist at Ospedali Riuniti, Polytechnic University of the Marche Region, Ancona, Italy.

    “Our experience indicates it may optimize functional outcomes. Before focal HIFU can be proposed as first-line treatment for localized prostate cancer, however, longer follow-up is needed to determine its effect on oncological control.”

    Next: Localization based on mpMRI, fusion Bx

    0 Comments

    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Poll